NCT03075904View on ClinicalTrials.gov

A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

January 16, 2019

Study Completion Date

January 16, 2019

Conditions
PemphigusPemphigus VulgarisPemphigus Foliaceus
Interventions
DRUG

ALXN1830

Administered via IV infusion.

Trial Locations (3)

19104

Alexion Study Site, Philadelphia

27516

Alexion Study Site, Chapel Hill

27710

Alexion Study Site, Durham

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY